Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Mihály Cserepes"'
Autor:
Sára Eszter Surguta, Marcell Baranyi, Laura Svajda, Mihály Cserepes, Ivan Ranđelović, Enikő Tátrai, Balázs Hegedűs, József Tóvári
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Lung cancer is the leading cause of cancer-related death globally. Metastasis is the most common reason of mortality in which hypoxia is suggested to have a pivotal role. However, the effect of hypoxia on the metastatic potential and migrato
Externí odkaz:
https://doaj.org/article/cb277a475cdd4d908f18552eefd4c861
Autor:
József Tóvári, Diána Vári-Mező, Sára Eszter Surguta, Andrea Ladányi, Attila Kigyós, Mihály Cserepes
Publikováno v:
Cells, Vol 12, Iss 14, p 1919 (2023)
Malignant melanoma is challenging to treat, and metastatic cases need chemotherapy strategies. Targeted inhibition of commonly mutant BRAF V600E by inhibitors is efficient but eventually leads to resistance and progression in the vast majority of cas
Externí odkaz:
https://doaj.org/article/e911b8ddcc184cc9bbfd3b98497b7a51
Autor:
Henriett Butz, Éva Saskői, Lilla Krokker, Viktória Vereczki, Alán Alpár, István Likó, Erika Tóth, Erika Szőcs, Mihály Cserepes, Katalin Nagy, Imre Kacskovics, Attila Patócs
Publikováno v:
Cells, Vol 12, Iss 5, p 784 (2023)
Background. The dual role of GCs has been observed in breast cancer; however, due to many concomitant factors, GR action in cancer biology is still ambiguous. In this study, we aimed to unravel the context-dependent action of GR in breast cancer. Met
Externí odkaz:
https://doaj.org/article/f58999a2c3d24be8b480e8bb5c8bb000
Autor:
Sabine Schmidhuber, Sandra Scheiblhofer, Richard Weiss, Mihály Cserepes, József Tóvári, Gabriele Gadermaier, Erwan Bezard, Francesca De Giorgi, François Ichas, Dirk Strunk, Markus Mandler
Publikováno v:
Vaccines, Vol 10, Iss 9, p 1432 (2022)
The progressive accumulation of misfolded α-synuclein (α-syn) in the brain is widely considered to be causal for the debilitating clinical manifestations of synucleinopathies including, most notably, Parkinson’s disease (PD). Immunotherapies, bot
Externí odkaz:
https://doaj.org/article/0e6a5cdac3be49cf99aba6c1fc8434f6
Autor:
Randa Naffa, Lisa Vogel, Luca Hegedűs, Katalin Pászty, Sarolta Tóth, Kornélia Kelemen, Neha Singh, Attila Reményi, Enikő Kállay, Mihály Cserepes, József Tóvári, Michael Grusch, Ágnes Enyedi
Publikováno v:
Cells, Vol 9, Iss 5, p 1209 (2020)
Metastatic melanoma is the most aggressive type of skin cancer. Previously, we identified the plasma membrane Ca2+ pump isoform 4b (PMCA4b or ATP2B4) as a putative metastasis suppressor in BRAF mutant melanoma cells. Metastasis suppressors are often
Externí odkaz:
https://doaj.org/article/94fa8bca835147719b519ff54ca79239
Autor:
Gergely Szakács, Norbert Szoboszlai, Jozsef Tovari, Pál T. Szabó, Christina Streli, Beáta G. Vértessy, György Várady, Nóra Kucsma, Judit E. Szabó, Melinda Gera, Anikó Gaál, Veronika F.S. Pape, Szilárd Tóth, Dóra Türk, Mihály Cserepes
Supplementary tables and figures, supplementary materials and methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e819c0db7a5bd45216d4aaf201c1b0d
https://doi.org/10.1158/0008-5472.22424827
https://doi.org/10.1158/0008-5472.22424827
Autor:
Gergely Szakács, Norbert Szoboszlai, Jozsef Tovari, Pál T. Szabó, Christina Streli, Beáta G. Vértessy, György Várady, Nóra Kucsma, Judit E. Szabó, Melinda Gera, Anikó Gaál, Veronika F.S. Pape, Szilárd Tóth, Dóra Türk, Mihály Cserepes
Clinical evidence shows that following initial response to treatment, drug-resistant cancer cells frequently evolve and, eventually, most tumors become resistant to all available therapies. We compiled a focused library consisting of >500 commerciall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d3bfd0cd96c275f4f36becbac6d1fe4
https://doi.org/10.1158/0008-5472.c.6511876
https://doi.org/10.1158/0008-5472.c.6511876
Autor:
Mihály Cserepes, Györgyi A. Nelhűbel, Mónika Meilinger-Dobra, Adrienn Herczeg, Dóra Türk, Zita Hegedűs, Laura Svajda, Erzsébet Rásó, Andrea Ladányi, Kristóf György Csikó, István Kenessey, Árpád Szöőr, György Vereb, Éva Remenár, József Tóvári
Publikováno v:
Cancers; Volume 14; Issue 10; Pages: 2407
Background: Head and neck squamous cell carcinomas (HNSCCs) are among the most abundant malignancies worldwide. Patients with recurrent/metastatic disease undergo combination chemotherapy containing cetuximab, the monoclonal antibody used against the
Autor:
Adél Kárpáti, Mihály Cserepes, László Őrfi, Györgyi A. Nelhűbel, Zita Hegedűs, József Tóvári, Erzsébet Rásó, Judit Dobos, Bálint Szokol, Tamás Barbai, Balázs Szabó, Dóra Türk, Viktoria Laszlo, István Kenessey
Publikováno v:
Pathology and Oncology Research
Background: Anti-EGFR antibody therapy is still one of the clinical choices in head and neck squamous cell carcinoma (HNSCC) patients, but the emergence of cetuximab resistance questioned its effectiveness and reduced its applicability. Although seve
Autor:
Mihály, Cserepes, Györgyi A, Nelhűbel, Mónika, Meilinger-Dobra, Sára Eszter, Surguta, Erzsébet, Rásó, Andrea, Ladányi, István, Kenessey, Árpád, Szöőr, György, Vereb, Éva, Remenár, József, Tóvári
Publikováno v:
Magyar onkologia. 65(2)
Head and neck squamous cell carcinomas (HNSCC) take many lifes worldwide. Patients with recurrent/metastatic disease receive combination chemotherapy containing anti-EGFR antibody cetuximab. However, resistance often hurdles therapy. The mechanism is